KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib

European Journal of Cancer

Volumn 49, Issue 10, 2013, Pages 2424-2432

  Smith, John C ^a   Brooks, Laura ^a   Hoff, Paulo M ^b,c   McWalter, Gael ^a   Dearden, Simon ^a   Morgan, Shethah R ^a   Wilson, David ^a   Robertson, Jane D ^a   Jürgensmeier, Juliane M ^a  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c HOSPITAL SÍRIO LIBANÊS   (Brazil)

Author keywords

Cediranib; Chemotherapy; Colorectal cancer; KRAS; Prognostic predictive marker

Indexed keywords

CEDIRANIB; K RAS PROTEIN; PLACEBO;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CODON; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; WILD TYPE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III AS TOPIC; CODON; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RAS PROTEINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84878383926     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.02.023     Document Type: Article

References (34)

1. E.R. Fearon, and B. Vogelstein A genetic model for colorectal tumorigenesis Cell 61 1990 759 767
2. S. Jones, W.D. Chen, and G. Parmigiani Comparative lesion sequencing provides insights into tumor evolution Proc Natl Acad Sci USA 105 2008 4283 4288
3. H.J. Andreyev, A.R. Norman, and D. Cunningham Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study Br J Cancer 85 2001 692 696
4. V. Bazan, M. Migliavacca, and I. Zanna Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype Ann Oncol 13 2002 1438 1446
5. G.Y. Locker, S. Hamilton, and J. Harris ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer J Clin Oncol 24 2006 5313 5327
6. C. Bokemeyer, I. Bondarenko, and A. Makhson Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 2009 663 671
7. E. Van Cutsem, I. Lang, and G. D'Haens KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience J Clin Oncol 26 15S 2008 abst 2A
8. R.G. Amado, M. Wolf, and M. Peeters Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 2008 1626 1634
9. B.A. Adelstein, T.A. Dobbins, C.A. Harris, I.C. Marschner, and R.L. Ward A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer Eur J Cancer 47 2011 1343 1354
10. A. Jimeno, W.A. Messersmith, F.R. Hirsch, W.A. Franklin, and S.G. Eckhardt KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection J Clin Oncol 27 2009 1130 1136
11. C.J. Allegra, J.M. Jessup, and M.R. Somerfield American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy J Clin Oncol 27 2009 2091 2096
12. T.S. Maughan, R.A. Adams, and C.G. Smith Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial Lancet 377 2011 2103 2114
13. J.-Y. Douillard, S. Siena, and J. Cassidy Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study J Clin Oncol 28 2010 4697 4705
14. M. Suenaga, S. Matsusaka, and K. Takagi Potential markers predicting bevacizumab efficacy for metastatic colorectal cancer patients J Clin Oncol 28 15S 2010 abst e14107
15. T.J. Price, J.E. Hardingham, and C.K. Lee Impact of KRAS and BRAF gene mutation status on outcomes from the Phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer J Clin Oncol 29 2011 2675 2682
16. W.L. Ince, A.M. Jubb, and S.N. Holden Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab J Natl Cancer Inst 97 2005 981 989
17. H.I. Hurwitz, J. Yi, W. Ince, W.F. Novotny, and O. Rosen The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer Oncologist 14 2009 22 28
18. S.R. Wedge, J. Kendrew, and L.F. Hennequin AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer Cancer Res 65 2005 4389 4400
19. E. Chen, D. Jonker, and I. Gauthier Phase I study of cediranib in combination with oxaliplatin and infusional 5-fluorouracil in patients with advanced colorectal cancer Clin Cancer Res 15 2009 1481 1486
20. P.M. Hoff, A. Hochhaus, and B.C. Pestalozzi Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, Phase III study (HORIZON II) J Clin Oncol 30 2012 3596 3603
21. D. Cunningham, R.P. Wong, and G. D'Haens A phase II, double-blind, randomized multicenter study of cediranib with FOLFOX versus bevacizumab with FOLFOX in patients with previously treated metastatic colorectal cancer (mCRC): final PFS results J Clin Oncol 26 15S 2008 abst 4028
22. T. Kato, K. Muro, and K. Yamaguchi Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: results from the randomised Phase II part of a Phase I/II study Ann Oncol 23 2012 933 941
23. C.R. Newton, A. Graham, and L.E. Heptinstall Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS) Nucleic Acids Res 17 1989 2503 2516
24. D. Whitcombe, J. Theaker, S.P. Guy, T. Brown, and S. Little Detection of PCR products using self-probing amplicons and fluorescence Nat Biotechnol 17 1999 804 807
25. S.A. Forbes, G. Tang, and N. Bindal COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer Nucleic Acids Res 38 2010 D652 D657
26. Wellcome Trust Sanger Institute. The Catalogue Of Somatic Mutations In Cancer (COSMIC) database. 22 July 2011. Available from http://www.sanger.ac.uk/ genetics/CGP/cosmic/.
27. C.P. Vaughn, S.D. Zobell, L.V. Furtado, C.L. Baker, and W.S. Samowitz Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer Genes Chromosomes Cancer 50 2011 307 312
28. A.D. Roth, S. Tejpar, and M. Delorenzi Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial J Clin Oncol 28 2010 466 474
29. M. Janakiraman, E. Vakiani, and Z. Zeng Genomic and biological characterization of exon 4 KRAS mutations in human cancer Cancer Res 70 2010 5901 5911
30. W. De Roock, D.J. Jonker, and F. Di Nicolantonio Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab JAMA 304 2010 1812 1820
31. W. De Roock, B. Claes, and D. Bernasconi Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncol 11 2010 753 762
32. E. Hawkes, and D. Cunningham Are we ready to restrict EGFR therapy to quadruple-negative colorectal cancer? Lancet Oncol 11 2010 1020 1021
33. S.D. Richman, M.T. Seymour, and P. Chambers KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial J Clin Oncol 27 2009 5931 5937
34. S. Ogino, J.A. Meyerhardt, and N. Irahara KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803 Clin Cancer Res 15 2009 7322 7329